Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Uniqure N.V. PAASHEUVELWEG 25 AMSTERDAM P7 1105 BP NLD

www.uniqure.com Employees: 480 P: 31-20-240-6000

Description:

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 274,302
Enterprise Value, $K 134,692
Shares Outstanding, K 48,549
Annual Sales, $ 15,840 K
Annual Net Income, $ -308,480 K
Last Quarter Sales, $ 11,130 K
Last Quarter Net Income, $ -56,300 K
EBIT, $ -241,870 K
EBITDA, $ -229,970 K
60-Month Beta 0.95
% of Insider Shareholders 4.74%
% of Institutional Shareholders 78.83%
Float, K 46,248
% Float 95.26%
Short Volume Ratio 0.61

Growth:

1-Year Return -13.76%
3-Year Return -80.18%
5-Year Return -88.59%
5-Year Revenue Growth 40.43%
5-Year Earnings Growth -176.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.16 on 08/01/24
Next Earnings Date 11/05/24
Earnings Per Share ttm -5.93
EPS Growth vs. Prev Qtr 14.71%
EPS Growth vs. Prev Year 19.44%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

QURE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -158.09%
Return-on-Assets % -35.54%
Profit Margin % -1,947.47%
Debt/Equity 1.06
Price/Sales 17.37
Price/Cash Flow N/A
Price/Book 2.83
Book Value/Share 1.99
Interest Coverage -6.38
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar